

# TACTIC: A SURVEY OF PAEDIATRIC TB POLICIES IN 14 COUNTRIES

## Summary Dashboard

Survey indicator	Afghanistan	Central African Republic <i>*Guidelines are being updated</i>	Democratic Republic of the Congo	Guinea <i>*Guidelines are being updated</i>	India	Mozambique	Niger	Nigeria	Pakistan <i>*Guidelines are being updated</i>	The Philippines	Sierra Leone	Somalia	South Sudan	Uganda <i>*Guidelines are being updated</i>	LEGEND		
DIAGNOSIS	DS-TB treatment for children can be initiated without bacteriological confirmation or chest X-ray (ie, based on clinical evaluation only)	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	WHO treatment decision algorithms are included in national policy documents	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	Xpert MTB/RIF Ultra test on stool specimens is included in national guidelines	NO	NO	NO	NO	no data	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	Operational research is undertaken to evaluate the use of Xpert MTB/RIF Ultra test on stool specimens	NO	NO	NO	NO	no data	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
PREVENTION	National guidelines recommend 3HR or 3HP as a short TPT regimen option for children below age 5 who are household contacts	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	National policies recommend 3HR or 3HP as a short TPT regimen option for children and adolescents living with HIV	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	TPT can be provided to PLHIV and children below age 5 without a test (TST and/or IGRA)	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
TREATMENT OF DS-TB	A 4-month treatment regimen for children and adolescents with non-severe DS-TB is included in national policies	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	Paediatric formulations of HR, HRZ and ethambutol are procured	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
TREATMENT OF DR-TB	National policies recommend the use of bedaquiline for children with DR-TB of all ages	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	National policies recommend the use of delamanid for children with DR-TB of all ages	NO	NO	NO	NO	Current use is limited to >10kg awaiting registration of for all age groups	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	Injectables are not recommended for children with MDR/RR-TB	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
	Paediatric formulations of bedaquiline and delamanid are procured	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
Paediatric formulations of other second-line TB drugs are procured	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO

\* The medicines required are levofloxacin 100mg dispersible tablet (dt), moxifloxacin 100mg dt, linezolid 150mg dt, clofazimine 50mg dt, cycloserine 125mg mini capsule, with moxifloxacin and levofloxacin interchangeable in currently recommended DR-TB regimens.